{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/vestibular-neuronitis/","result":{"data":{"firstChapter":{"id":"1371e2f5-4cd3-5674-aae3-79470e21b62b","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 79741d22-3dc0-4afb-a8d9-e4b59a2beff5 --><h1>Vestibular neuronitis: Summary</h1><!-- end field 79741d22-3dc0-4afb-a8d9-e4b59a2beff5 -->","htmlStringContent":"<!-- begin item 4b9980b1-3a16-414e-ba9e-81c4c2b1b3e0 --><!-- begin field bbcec9ce-bf50-4e5f-aa4e-f4ff8d2f5301 --><ul><li>Vestibular neuronitis (sometimes called vestibular neuritis) is a disorder characterised by acute, isolated, spontaneous, and prolonged vertigo of peripheral origin.</li><li>The terms 'vestibular neuronitis' and 'labyrinthitis' have been used interchangeably in the past, but specific terminology is now recommended by experts.<ul><li>Vestibular neuronitis is thought to be due to inflammation of the vestibular nerve and often occurs after a viral infection.</li><li>Labyrinthitis is a different diagnosis that involves inflammation of the labyrinth. </li><li>Hearing loss is a feature of labyrinthitis, but hearing is <em>not </em>affected in vestibular neuronitis.</li></ul></li><li>Although the severe initial symptoms usually last 2–3 days, people with vestibular neuronitis usually recover gradually over a period of weeks through a process of central nervous system compensation. </li><li>Symptoms of vestibular neuronitis include spontaneous onset of vertigo, nausea, vomiting, and unsteadiness. Hearing loss and tinnitus are <em>not </em>present, and there are no focal neurological symptoms.</li><li>Signs include:<ul><li>Presence of nystagmus - usually fine horizontal but may be mixed horizontal-torsional with the fast phase away from the affected ear. It always beats in the same direction, even if the head is rotated, and is reduced when the vision is fixed on a point.</li><li>The head impulse test may be positive (but may also be positive for other peripheral causes of vertigo).</li></ul></li><li>Differential diagnosis of vertigo includes benign paroxysmal positional vertigo, labyrinthitis, Meniere’s disease, and central causes such as migraine, stroke, cerebellar tumour, and multiple sclerosis.</li><li>Advice should be offered regarding resuming activity as soon as possible, and safety issues such as driving, work, and prevention of falls.</li><li>If symptoms are severe, short-term symptomatic drug treatment can be offered.<ul><li>Buccal or intramuscular prochlorperazine or intramuscular cyclizine can be considered to rapidly relieve severe nausea or vomiting associated with vertigo.</li><li>A short course of oral prochlorperazine, cinnarizine, cyclizine, or promethazine teoclate can be considered to alleviate less severe nausea, vomiting, and vertigo.</li></ul></li><li>If nausea and vomiting is so severe that a person cannot tolerate oral fluids or symptomatic drug treatment, they should be admitted to hospital.</li><li>Referral is necessary if there are atypical symptoms (for example additional neurological symptoms), symptoms are not improving after a week of treatment, or symptoms persist for more than 6 weeks.</li></ul><!-- end field bbcec9ce-bf50-4e5f-aa4e-f4ff8d2f5301 --><!-- end item 4b9980b1-3a16-414e-ba9e-81c4c2b1b3e0 -->","topic":{"id":"4161326f-3a9d-549b-a377-dc2f2a6f809a","topicId":"d53e1081-ae57-4dcc-8ee8-14e6be6fb3d6","topicName":"Vestibular neuronitis","slug":"vestibular-neuronitis","aliases":[],"chapters":[{"id":"1371e2f5-4cd3-5674-aae3-79470e21b62b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"cb3f7155-69a7-5a7f-b8c1-2a1a113f0070","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"a45dcd81-fea0-598a-ba01-782b350ffabd","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"06a83e39-ba88-5cb5-872a-7b5e56e06a3c","slug":"changes","fullItemName":"Changes"},{"id":"c9683178-6f5b-5445-a2d4-02d27c379f4b","slug":"update","fullItemName":"Update"}]},{"id":"a9baddc3-bb87-54e7-b6bf-fb890ce8d86d","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"65c0b807-ad55-5cb6-8ac0-1beaf353fd29","slug":"goals","fullItemName":"Goals"},{"id":"c577b7a6-4f03-5974-a443-32000f43d67c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"300cd325-7e03-5d62-afb6-803945166705","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e3892d6-0403-52e9-a509-fc65bd12340b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c67ef3c1-dad6-5fbc-9fc2-1f9ef2f8fcef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e83fe4f4-878e-59eb-a20b-f35218ed5023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4fd633a-c05b-5b41-9dc2-d862bc4286b5","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"8ab4ebcd-03e4-5892-9e29-aabb20cb8f45","slug":"definition","fullItemName":"Definition"},{"id":"552f3d90-3666-593b-b806-28115dcd8f3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1966c14e-e128-5b21-bbce-6b9d4f48924d","slug":"complications","fullItemName":"Complications"},{"id":"f30ad763-2643-586e-9d19-cffd5f45d021","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"adbff71b-d255-5959-953d-3b2788094c8b","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"081f5ce9-172b-5beb-9ace-bbe7a9e86705","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ba7e323e-e894-5821-9164-ea7cd07a38b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7c05a5c3-6c86-5daa-aed5-df8280f3723a","slug":"management","fullItemName":"Management","subChapters":[{"id":"f6abc1bb-cef0-5ec3-abe6-ca99c3f79fa7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"1ae90a52-6113-534c-8cf7-46d78bb039a3","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"354fa7f8-799b-53ab-900a-b4083df52ec8","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"4df87a4b-4d5c-56b0-b766-c143a60b38e8","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"ac9da5a7-a091-516f-a6b1-03ed2d2f7156","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"9f00019c-78be-54da-b9cb-69c6c04c5063","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"c39d54c3-45ec-52b9-9dd2-efc3f3caa200","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"d04e0140-1610-5826-9319-63f03c35c2d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"763af5f7-891e-5c76-9970-ae093e35ae7b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d0088dd9-7199-53a5-a4d0-e4299a54c061","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c9ae115f-4e3a-5af0-870e-16c967836515","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"27450791-3a41-5a8d-951b-efe744ca7944","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49115179-8551-5f4b-9d71-06a60c3445da","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"4161326f-3a9d-549b-a377-dc2f2a6f809a","topicId":"d53e1081-ae57-4dcc-8ee8-14e6be6fb3d6","topicName":"Vestibular neuronitis","slug":"vestibular-neuronitis","aliases":[],"topicSummary":"Vestibular neuronitis (sometimes called vestibular neuritis) is a disorder characterised by acute, isolated, spontaneous, and prolonged vertigo","lastRevised":"Last revised in November 2017","nextPlannedReviewBy":"2022-11-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2022-11","nextPlannedReviewByDisplay":"November 2022","specialities":[{"id":"bb606678-e2cc-550b-bd11-bd7b8e7d05e1","name":"Ear, nose and throat","slug":"ear-nose-throat"},{"id":"08590215-7450-5fd4-bb09-b98865ce23ee","name":"Neurological","slug":"neurological"}],"chapters":[{"id":"1371e2f5-4cd3-5674-aae3-79470e21b62b","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"cb3f7155-69a7-5a7f-b8c1-2a1a113f0070","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"a45dcd81-fea0-598a-ba01-782b350ffabd","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"06a83e39-ba88-5cb5-872a-7b5e56e06a3c","slug":"changes","fullItemName":"Changes"},{"id":"c9683178-6f5b-5445-a2d4-02d27c379f4b","slug":"update","fullItemName":"Update"}]},{"id":"a9baddc3-bb87-54e7-b6bf-fb890ce8d86d","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"65c0b807-ad55-5cb6-8ac0-1beaf353fd29","slug":"goals","fullItemName":"Goals"},{"id":"c577b7a6-4f03-5974-a443-32000f43d67c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"300cd325-7e03-5d62-afb6-803945166705","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4e3892d6-0403-52e9-a509-fc65bd12340b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c67ef3c1-dad6-5fbc-9fc2-1f9ef2f8fcef","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e83fe4f4-878e-59eb-a20b-f35218ed5023","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d4fd633a-c05b-5b41-9dc2-d862bc4286b5","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"8ab4ebcd-03e4-5892-9e29-aabb20cb8f45","slug":"definition","fullItemName":"Definition"},{"id":"552f3d90-3666-593b-b806-28115dcd8f3b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1966c14e-e128-5b21-bbce-6b9d4f48924d","slug":"complications","fullItemName":"Complications"},{"id":"f30ad763-2643-586e-9d19-cffd5f45d021","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"adbff71b-d255-5959-953d-3b2788094c8b","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"081f5ce9-172b-5beb-9ace-bbe7a9e86705","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ba7e323e-e894-5821-9164-ea7cd07a38b4","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7c05a5c3-6c86-5daa-aed5-df8280f3723a","slug":"management","fullItemName":"Management","subChapters":[{"id":"f6abc1bb-cef0-5ec3-abe6-ca99c3f79fa7","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"ac81d77a-e9b5-5b14-9a42-63c17716a3f4","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"1ae90a52-6113-534c-8cf7-46d78bb039a3","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"354fa7f8-799b-53ab-900a-b4083df52ec8","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"4df87a4b-4d5c-56b0-b766-c143a60b38e8","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"ac9da5a7-a091-516f-a6b1-03ed2d2f7156","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"9f00019c-78be-54da-b9cb-69c6c04c5063","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"c39d54c3-45ec-52b9-9dd2-efc3f3caa200","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"d04e0140-1610-5826-9319-63f03c35c2d1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"763af5f7-891e-5c76-9970-ae093e35ae7b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d0088dd9-7199-53a5-a4d0-e4299a54c061","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"c9ae115f-4e3a-5af0-870e-16c967836515","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"27450791-3a41-5a8d-951b-efe744ca7944","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"49115179-8551-5f4b-9d71-06a60c3445da","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"4161326f-3a9d-549b-a377-dc2f2a6f809a"}},"staticQueryHashes":["3666801979"]}